Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says
This article was originally published in The Pink Sheet Daily
The letter details problems related to Baxter's use of albumin in the manufacturing of its Isolex 300i Magnetic Cell Selection System, a device/biologic regulated as a Class III device.
You may also be interested in...
FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.
An FDA warning letter charges that promotional materials for Baxter's Tisseel fibrin sealant constitute misbranding of the product
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.